<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03583333</url>
  </required_header>
  <id_info>
    <org_study_id>7655A-016</org_study_id>
    <secondary_id>MK-7655A-016</secondary_id>
    <secondary_id>2018-003202-82</secondary_id>
    <secondary_id>PHRR190814-002177</secondary_id>
    <nct_id>NCT03583333</nct_id>
  </id_info>
  <brief_title>Imipenem/Cilastatin/Relebactam (MK-7655A) Versus Piperacillin/Tazobactam in Participants With Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia (MK-7655A-016)</brief_title>
  <official_title>A Multi-national Phase 3, Randomized, Double-Blind, Active Comparator-Controlled Clinical Trial to Study the Safety, Tolerability, and Efficacy of Imipenem/Cilastatin/Relebactam (MK-7655A) Versus Piperacillin/Tazobactam in Subjects With Hospital-Acquired Bacterial Pneumonia or Ventilator-Associated Bacterial Pneumonia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the efficacy and safety of imipenem/cilastatin/relebactam (IMI/REL)
      (MK-7655A) compared to piperacillin/tazobactam (PIP/TAZ) in the treatment of adults diagnosed
      with Hospital-Acquired Bacterial Pneumonia (HABP) or Ventilator-Associated Bacterial
      Pneumonia (VABP). The primary hypothesis is that IMI/REL is non-inferior to PIP/TAZ as
      measured by the incidence rate of all-cause mortality through Day 28 post-randomization.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 18, 2018</start_date>
  <completion_date type="Anticipated">April 25, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 25, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>Up to Day 28</time_frame>
    <description>Percentage of participants with all-cause mortality through Day 28</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Favorable clinical response at end of treatment (EOT) visit</measure>
    <time_frame>From treatment Day 7 up to Day 15</time_frame>
    <description>Percentage of participants achieving a favorable clinical response at EOT visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Favorable clinical response at early follow-up (EFU) visit</measure>
    <time_frame>7-14 days post-EOT (up to Day 28)</time_frame>
    <description>Percentage of participants achieving a favorable clinical response at EFU visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Favorable microbiological response at EFU visit.</measure>
    <time_frame>7-14 days post-EOT (up to Day 28)</time_frame>
    <description>Percentage of participants achieving a favorable microbiological response at EFU visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Favorable microbiological response at EOT visit.</measure>
    <time_frame>From treatment Day 7 up to Day 15</time_frame>
    <description>Percentage of participants achieving a favorable microbiological response at EOT visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Up to Day 31</time_frame>
    <description>Number of participants experiencing adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Discontinuations due to adverse events</measure>
    <time_frame>Up to Day 14</time_frame>
    <description>Number of participants discontinuing study drug due to adverse events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">270</enrollment>
  <condition>Hospital-Acquired Bacterial Pneumonia</condition>
  <condition>Ventilator-Associated Bacterial Pneumonia</condition>
  <arm_group>
    <arm_group_label>IMI/REL FDC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Imipenem/cilastatin/relebactam (IMI/REL) administered intravenously (IV) as a fixed-dose combination (FDC) at a dosage of 500 mg IMI/250 mg REL/500 mg Cilastatin, once every 6 hours for a minimum 7 days, up to 14 days. At the start of IMI/REL treatment, participants will be treated empirically with 600 mg open-label linezolid administered IV every 12 hours until methicillin-resistant Staphylococcus aureus (MRSA) is ruled out. Participants with confirmed MRSA infection will continue to receive 600 mg linezolid every 12 hours for a minimum of 7 days, up to 14 days total.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PIP/TAZ FDC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Piperacillin/tazobactam (PIP/TAZ ) administered IV as a FDC at a dosage of 4000 mg PIP/500 mg TAZ once every 6 hours for a minimum 7 days, up to 14 days. At the start of PIP/TAZ treatment, participants will be treated empirically with 600 mg open-label linezolid administered IV every 12 hours until methicillin-resistant Staphylococcus aureus (MRSA) is ruled out. Participants with confirmed MRSA infection will continue to receive 600 mg linezolid every 12 hours for a minimum of 7 days, up to 14 days total.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IMI/REL FDC</intervention_name>
    <description>500 mg Imipenem, 500 mg Cilastatin and 250 mg Relebactam powder FDC provided in a single vial</description>
    <arm_group_label>IMI/REL FDC</arm_group_label>
    <other_name>MK-7655A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PIP/TAZ FDC</intervention_name>
    <description>4000 mg Piperacillin and 500 mg Tazobactam powder FDC provided in a single vial</description>
    <arm_group_label>PIP/TAZ FDC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Linezolid</intervention_name>
    <description>Open-label 600 mg Linezolid</description>
    <arm_group_label>IMI/REL FDC</arm_group_label>
    <arm_group_label>PIP/TAZ FDC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Requires treatment with IV antibiotic therapy for HABP or VABP

          -  Fulfills clinical and radiographic criteria, with onset of criteria occurring after
             more than 2 days of hospitalization or within 7 days after discharge from a hospital
             for HABP; or at least 2 days after mechanical ventilation (for VABP)

          -  Has an adequate baseline (at or within 2 days of screening) lower respiratory tract
             specimen obtained for Gram stain and culture

          -  Has an infection known or thought to be, in the opinion of the investigator, caused by
             microorganisms susceptible to the IV study therapy

          -  Agrees to allow any bacterial isolates obtained from protocol-required specimens
             related to the current infection to be provided to the Central Microbiology Reference
             Laboratory for study-related microbiological testing and long-term storage

          -  Males agree to use contraception as detailed in protocol from the time of providing
             informed consent through completion of the study and refrain from donating sperm
             during this period

          -  Females are not pregnant, not breastfeeding, and are either: a.) Not a woman of
             childbearing potential (WOCBP) OR b.) A WOCBP who agrees to follow the contraceptive
             guidance from the time of providing informed consent through completion of the study

          -  If a penicillin skin test is required by local clinical practice, the participant must
             have a negative skin test result for allergy to penicillin

        Exclusion Criteria:

          -  Has a baseline lower respiratory tract specimen Gram stain that shows the presence of
             Gram-positive cocci only

          -  Has confirmed or suspected community-acquired bacterial pneumonia (CABP)

          -  Has confirmed or suspected pneumonia caused by Mycoplasma, Chlamydia, or Legionella,
             or of viral, fungal, or parasitic etiology

          -  Has HABP/VABP caused by an obstructive process, including lung cancer (or other
             malignancy metastatic to the lungs resulting in pulmonary obstruction) or other known
             obstruction

          -  Has a carcinoid tumor or carcinoid syndrome

          -  Has active immunosuppression

          -  Is expected to die during the 7- to 14-day treatment period, despite adequate
             antibiotic therapy

          -  Has a concurrent condition or infection that, in the investigator's judgment, would
             preclude evaluation of therapeutic response

          -  Has a history of serious allergy, hypersensitivity, or any serious reaction to any
             β-lactams or β-lactamase inhibitors

          -  Has a history of a seizure disorder which has required ongoing treatment with
             anticonvulsive therapy or prior treatment with anti-convulsive therapy within the last
             3 years

          -  Is currently undergoing hemodialysis or peritoneal dialysis

          -  A WOCBP who has a positive urine pregnancy test at screening

          -  Has received effective antibacterial drug therapy with known coverage of pathogens
             that cause HABP/VABP for a continuous duration of more than 48 hours during the
             previous 72 hours

          -  Is anticipated to be treated with any of the prohibited medications during the course
             of study therapy

          -  Is currently participating in, or has participated in, any other clinical study
             involving the administration of investigational or experimental medication (not
             licensed by regulatory agencies) at the time of the presentation or during the
             previous 90 days prior to screening or is anticipated to participate in such a
             clinical study during the course of this trial

          -  Has previously participated in this study at any time
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
    <email>Trialsites@merck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Santa Casa de Misericordia de Belo Horizonte ( Site 0300)</name>
      <address>
        <city>Belo Horizonte</city>
        <state>Minas Gerais</state>
        <zip>30150-221</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+553132388849</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital de Base de Sao Jose de Rio Preto ( Site 0301)</name>
      <address>
        <city>Sao Jose Do Rio Preto - SP</city>
        <state>Sao Paulo</state>
        <zip>15090-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+551732015054</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Chaoyang Hospital ( Site 0126)</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100020</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+861085231000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peking University First Hospital ( Site 0131)</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100034</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+861066119025</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aero Space center hospital ( Site 0118)</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100049</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+8613611106725</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peking University Third Hospital ( Site 0115)</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100191</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+8613910125933</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Hospital ( Site 0127)</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+8613701097436</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Affiliated Union Hospital of Fujian Medical University ( Site 0136)</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+8613850188717</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhongshan Hospital Xiamen University ( Site 0133)</name>
      <address>
        <city>Xiamen</city>
        <state>Fujian</state>
        <zip>361004</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+8613860193547</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital ( Site 0100)</name>
      <address>
        <city>GuangZhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+862087333133</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Guangzhou Medical University ( Site 0123)</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510120</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+8613902273260</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Guangzhou First People's Hospital ( Site 0101)</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510180</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+862081048888</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southern Medical University Nanfang Hospital ( Site 0120)</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+8613119545239</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shenzhen People s Hospital ( Site 0134)</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangdong</state>
        <zip>518020</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+8675525533018</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hainan General Hospital ( Site 0106)</name>
      <address>
        <city>Haikou</city>
        <state>Hainan</state>
        <zip>570311</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+8689868662261</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Zhengzhou University ( Site 0121)</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450052</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+86037166271097</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Changsha Central Hospital ( Site 0119)</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410004</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+8673185667872</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hunan Provincial People Hospital ( Site 0122)</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410005</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+8673183929310</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>First Hospital Affiliated to Suzhou University ( Site 0111)</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <zip>215008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+8651267780040</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wuxi People's Hospital ( Site 0124)</name>
      <address>
        <city>Wuxi</city>
        <state>Jiangsu</state>
        <zip>214023</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+86051085350348</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital of Jiangsu University ( Site 0147)</name>
      <address>
        <city>Zhenjiang</city>
        <state>Jiangsu</state>
        <zip>212000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>077112636306</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jiangxi Provincial People's Hospital ( Site 0129)</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <zip>330006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+8679186895863</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Nanchang University ( Site 0132)</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <zip>330006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+8613707089183</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of China Medical University ( Site 0116)</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+8602483282836</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>General Hospital of Ningxia Medical University ( Site 0135)</name>
      <address>
        <city>Yinchuan</city>
        <state>Ningxia</state>
        <zip>750004</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+8609516744631</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ruijin Hospital Shanghai Jiao Tong University School of Medicine ( Site 0104)</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+8602134186000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Huadong Hospital Affiliated Fudan University ( Site 0103)</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200040</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>860216248318028408</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Huashan Hospital of Fudan University ( Site 0105)</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200040</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+8621528899</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai General Hospital ( Site 0125)</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+8602163240090</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai Pulmonary Hospital ( Site 0108)</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200443</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>862165115006</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tianjin Medical University General Hospital ( Site 0113)</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300052</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+8602260361044</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital.Zhejiang University ( Site 0102)</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+8613505719970</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sir Run Run Shaw Hospital School of Medicine, Zhejiang University ( Site 0110)</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310016</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+86057186006102</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The 2nd Affiliated Hospital of Wenzhou Medical University ( Site 0130)</name>
      <address>
        <city>Wenzhou</city>
        <state>Zhejiang</state>
        <zip>325000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+8613857715778</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes - Hotel Dieu ( Site 0600)</name>
      <address>
        <city>Nantes</city>
        <state>Loire-Atlantique</state>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33240083005</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Roger Salengro du Lille ( Site 0601)</name>
      <address>
        <city>Lille</city>
        <state>Nord</state>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3320444495</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospices Civils de Lyon ( Site 0603)</name>
      <address>
        <city>Pierre Benite</city>
        <state>Rhone</state>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33478861918</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Bicetre ( Site 0605)</name>
      <address>
        <city>Le Kremlin-Bicetre</city>
        <state>Val-de-Marne</state>
        <zip>94270</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33145213544</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Civil de Guadalajara Fray Antonio Alcalde ( Site 0800)</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44280</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+523338095379</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Civil Nuevo de Guadalajara Dr. Juan I. Menchaca ( Site 0804)</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44340</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+523336583705</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mary Johnston Hospital ( Site 0901)</name>
      <address>
        <city>Metro Manila</city>
        <state>National Capital Region</state>
        <zip>1012</zip>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+639175878699</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lung Center of the Philippines ( Site 0903)</name>
      <address>
        <city>Quezon</city>
        <state>National Capital Region</state>
        <zip>1104</zip>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+639178999610</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>West Visayas State University Medical Center ( Site 0900)</name>
      <address>
        <city>Iloilo</city>
        <zip>5000</zip>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+639189070975</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic Judetean de Urgenta Pius Branzeu ( Site 1103)</name>
      <address>
        <city>Timisoara</city>
        <state>Timis</state>
        <zip>300723</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+40748331192</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic de Urgenta Bagdasar-Arseni ( Site 1101)</name>
      <address>
        <city>Bucuresti</city>
        <zip>041915</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+40741078026</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>First City Clinical Hospital n.a. E.E.Volosevich ( Site 1016)</name>
      <address>
        <city>Arkhangelsk</city>
        <state>Arkhangel'skaya Oblast'</state>
        <zip>163001</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79217215691</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>City Hospital #2 Severodvinsk ( Site 1017)</name>
      <address>
        <city>Severodvinsk</city>
        <state>Arkhangel'skaya Oblast'</state>
        <zip>164500</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79021980555</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Institute of Emergency Medicine n.a. I.I.Dzhanelidze ( Site 1011)</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Sankt-Peterburg</state>
        <zip>192242</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+78123844646</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital #122 L.G. Sokolova FMBA ( Site 1015)</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Sankt-Peterburg</state>
        <zip>194291</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>City Hospital #26 ( Site 1002)</name>
      <address>
        <city>Saint-Petersburg</city>
        <state>Sankt-Peterburg</state>
        <zip>196247</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>ME Dnipropetrovsk Clinical Joinder of Emergency Care of DRC ( Site 1304)</name>
      <address>
        <city>Dnipro</city>
        <state>Dnipropetrovska Oblast</state>
        <zip>49006</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380503614270</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ivano-Frankivsk regional clinical hospital ( Site 1301)</name>
      <address>
        <city>Ivano-Frankivsk</city>
        <state>Ivano-Frankivska Oblast</state>
        <zip>76008</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380342528183</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital No13 of Kharkiv City Council ( Site 1303)</name>
      <address>
        <city>Kharkiv</city>
        <state>Kharkivska Oblast</state>
        <zip>61124</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380577210948</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kiyv city municipal hospital 17 ( Site 1300)</name>
      <address>
        <city>Kiev</city>
        <state>Kyivska Oblast</state>
        <zip>01133</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380445292472</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Reg. Clin. Hospital ( Site 1306)</name>
      <address>
        <city>Poltava</city>
        <state>Poltavska Oblast</state>
        <zip>36000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380662369670</phone>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>China</country>
    <country>France</country>
    <country>Mexico</country>
    <country>Philippines</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Ukraine</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 28, 2018</study_first_submitted>
  <study_first_submitted_qc>June 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 11, 2018</study_first_posted>
  <last_update_submitted>July 10, 2020</last_update_submitted>
  <last_update_submitted_qc>July 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia, Bacterial</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Linezolid</mesh_term>
    <mesh_term>MK-7655</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

